<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898179</url>
  </required_header>
  <id_info>
    <org_study_id>ICS Maugeri CE2455</org_study_id>
    <nct_id>NCT04898179</nct_id>
  </id_info>
  <brief_title>Support for COVID19 Patients at Home</brief_title>
  <acronym>Mirato</acronym>
  <official_title>Targed Support for Patients Discharged After Hospitalization for SARS-CoV-2 Infection and Comorbidities. [ITALIAN. Supporto MIRATO ai Pazienti Dimessi Dopo un Ricovero Per Infezione da SARS-CoV-2 e comorbidit√†]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituti Clinici Scientifici Maugeri SpA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Auxologico Italiano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Bolognini di Seriate Bergamo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Socio Sanitaria Territoriale di Bergamo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bergamo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituti Clinici Scientifici Maugeri SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rapid spread and increase of acute respiratory infection cases caused by the novel&#xD;
      SARS-CoV-2 coronavirus represent a major challenge for healthcare systems around the world.&#xD;
      The shortage of facilities and medical personnel is a major problem in the face of a serious&#xD;
      epidemic. The Lombardy Region, and in particular the territories of Milan, Bergamo and&#xD;
      Brescia, was the most affected due to the rapid increase in cases and limited medical&#xD;
      resources during the initial phase of the epidemic.&#xD;
&#xD;
      The collaboration between hospital and territory with integrated communication systems and&#xD;
      the monitoring of patients with appropriate technological tools that include telemedicine,&#xD;
      are fundamental to ensure the continuity of care and the sustainability of the health system,&#xD;
      also significantly reducing the risk of contagion for health professionals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MIRATO Project wants to test the remote health surveillance services and a telemonitoring&#xD;
      program for patients discharged after a period of hospitalization for COVID19 caused by the&#xD;
      new coronavirus SARS-CoV-2 and their comorbidities if present.&#xD;
&#xD;
      Patients discharged from hospitals still present in many cases breathing difficulties, bed&#xD;
      rest symptoms and other disabilities related to the acute event. In addition, some patients&#xD;
      are seeing rekindling of symptoms such as fever, dry cough, difficulty respiratory and blood&#xD;
      desaturation into oxygen. These problems underline the need for procedures that allow us to&#xD;
      safely discharge patients to be able to better follow their convalescence but also to be able&#xD;
      to intervene quickly in the event of symptoms returning.&#xD;
&#xD;
      The purpose of the home health surveillance intervention will be:&#xD;
&#xD;
        -  Monitor the evolution of the state of health with standardized tools based on scientific&#xD;
           evidence&#xD;
&#xD;
        -  Provide counselling support to help recovery&#xD;
&#xD;
        -  Have certain and early identification of signs and symptoms related to a possible&#xD;
           resumption of the COVID19 pathology and or to comorbidities&#xD;
&#xD;
        -  Compare outcome results with case-control design three months after hospital discharge&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Re-hospitalisation at three months</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Re-hospitalisation registered at three months period in two groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ER access at three months</measure>
    <time_frame>3 months</time_frame>
    <description>Number of ER accesses registered at three months period in two groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death at three months</measure>
    <time_frame>3 months</time_frame>
    <description>Number of death at three months in two groups</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COVID19 Patients</condition>
  <arm_group>
    <arm_group_label>Telecare group</arm_group_label>
    <description>When discharged, patients will be followed at home by a telecare nursing and specialist teleconsultation program for 3 months. The key element of the program will be a structured nurse-managed telephone support and, when necessary, video consultations, to follow patients, for the first month. During these contacts, the nurse will conduct a standardized interview enquiring about the general clinical condition of the patient. In the case of any symptom or problem, the patient will be able to call the service. At the end of the third month, patients will contact again to check their clinical condition and to close the program. Patients will be provided with a pulse oximeter to measure O2 saturation.&#xD;
At the start and end of the program, patients were administered the SF-12 quality of life questionnaire.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>The patients in the control group will be followed by their general practitioner and they will be contacted after three months to check their clinical condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telecare Group</intervention_name>
    <description>Home-based telehealth program: telenursing and specialist teleconsultation&#xD;
Telemonitoring with a new pulse oximeter and specific App&#xD;
E-health platform&#xD;
Videoconference</description>
    <arm_group_label>Telecare group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>Usual care</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients hospitalized for COVID19&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalisation for COVID19&#xD;
&#xD;
          -  Patients discharged at home&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Patients discharged at a nursing home&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simonetta Scalvini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituti Clinici Scientifici Maugeri</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Palmira Bernocchi, PhD</last_name>
    <phone>+390308253</phone>
    <phone_ext>260</phone_ext>
    <email>palmira.bernocchi@icsmaugeri.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paola Baiardi, PhD</last_name>
    <phone>+390382592</phone>
    <phone_ext>599</phone_ext>
    <email>paola.baiardi@icsmaugeri.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale (ASST) BERGAMO EST, Ospedale Bolognini di Seriate</name>
      <address>
        <city>Seriate</city>
        <state>Bergamo</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Giudici, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrizia Rocca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luigina Viscardi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paola Neri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ics Maugeri</name>
      <address>
        <city>Lumezzane</city>
        <state>Brescia</state>
        <zip>25065</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simonetta Scalvini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emanuela Zanelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ics Maugeri</name>
      <address>
        <city>Tradate</city>
        <state>Varese</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Angeli, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Samantha Chiara Mingardi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Auxologico Italiano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianfranco Parati, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Elisa Perger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Word Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available at https://covid19.who.int 2020. (last accessed March 2021).</citation>
  </reference>
  <reference>
    <citation>Tebeje TH, Klein J. Applications of e-Health to Support Person-Centered Health Care at the Time of COVID-19 Pandemic. Telemed J E Health. 2021 Feb;27(2):150-158. doi: 10.1089/tmj.2020.0201. Epub 2020 Jul 31.</citation>
    <PMID>32746750</PMID>
  </reference>
  <reference>
    <citation>Doshi A, Platt Y, Dressen JR, Mathews BK, Siy JC. Keep Calm and Log On: Telemedicine for COVID-19 Pandemic Response. J Hosp Med. 2020 May;15(5):302-304. doi: 10.12788/jhm.3419. Epub 2020 Apr 1.</citation>
    <PMID>32379036</PMID>
  </reference>
  <reference>
    <citation>Tabacof L, Kellner C, Breyman E, Dewil S, Braren S, Nasr L, Tosto J, Cortes M, Putrino D. Remote Patient Monitoring for Home Management of Coronavirus Disease 2019 in New York: A Cross-Sectional Observational Study. Telemed J E Health. 2021 Jun;27(6):641-648. doi: 10.1089/tmj.2020.0339. Epub 2020 Oct 13.</citation>
    <PMID>33232204</PMID>
  </reference>
  <reference>
    <citation>Scalvini S, Bernocchi P, Zanelli E, Comini L, Vitacca M; Maugeri Centre for Telehealth and Telecare (MCTT). Maugeri Centre for Telehealth and Telecare: A real-life integrated experience in chronic patients. J Telemed Telecare. 2018 Aug;24(7):500-507. doi: 10.1177/1357633X17710827. Epub 2017 May 24.</citation>
    <PMID>28537509</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

